The study demonstrates the potential for the B-cell modulator, atacicept, to address the underlying pathogenesis of IgA nephropathy by binding BAFF and APRIL, resulting in reductions in pathogenic forms of IgA, hematuria, and proteinuria and a stable eGFR profile. This evidence concerns the gene TNFSF13 and IgA glomerulonephritis.